接受富马酸替诺福韦二吡呋酯预防乙肝母婴传播的孕妇肾近端小管功能障碍
本研究利用在泰国开展的III期多中心随机双盲安慰剂对照临床试验的尿样,评估HBV单一感染孕妇从孕28周至产后2个月服用富马酸替诺福韦二吡呋酯预防母婴传播时近端小管功能障碍的风险。共291名女性参与,产后2个月替诺福韦组120名中3名(3%)出现近端小管病变,安慰剂组125名中3名(2%)出现,P=1.00。结论认为在该人群中替诺福韦用药与近端小管病变风险升高无关。
要点
- 产后2个月替诺福韦组近端小管病变3/120(3%),安慰剂组3/125(2%),P=1.00。
- 无严重肾脏不良事件,无因替诺福韦停药者。
- 6名近端小管病变女性在产后12个月均不符合诊断标准,但3名蛋白尿持续。
核心结论
- 在HBV感染的妊娠及哺乳期女性中,从孕28周至产后2个月给予富马酸替诺福韦二吡呋酯与近端小管病变风险升高无关。
研究设计与样本
- 利用在泰国开展的III期、多中心、随机、双盲、安慰剂对照临床试验的尿样,评估孕28周至产后2个月富马酸替诺福韦二吡呋酯短程方案预防HBV母婴传播。
- 共291名HBV单一感染孕妇参与,在孕28周、孕32周和产后2个月检测肾小管功能障碍标志物。
主要发现
- 产后2个月,替诺福韦组120名受评估者中3名(3%)出现近端小管病变,安慰剂组125名中3名(2%)出现,P=1.00。
- 无严重肾脏相关不良事件,无因此停用替诺福韦者。
- 6名近端小管病变女性在产后12个月均不符合诊断标准,但其中3名蛋白尿持续。
- 产后2个月有近端小管病变的母亲所生婴儿在1岁时未发现生长异常。
关键数值与推荐
- 近端小管病变定义为以下≥2项存在:肾小管性蛋白尿、血糖正常性糖尿、尿磷升高。
- 检测的肾小管功能障碍标志物包括视黄醇结合蛋白、肾损伤分子-1、α1-微球蛋白和β2-微球蛋白。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data evaluating the risk of proximal tubular dysfunction in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission (PMTCT) of HBV are scarce. OBJECTIVES: To assess the risk of proximal tubulopathy in pregnant women receiving tenofovir disoproxil fumarate for PMTCT of HBV. PATIENTS AND METHODS: We used urine samples collected from HBV monoinfected pregnant women who participated in a Phase III, multicentre, randomized, double-blind, placebo-controlled clinical trial assessing a tenofovir disoproxil fumarate short course from 28 weeks gestational age (28-wk-GA) to 2 months post-partum (2-months-PP) for PMTCT of HBV in Thailand. Markers of tubular dysfunction, including retinol binding protein, kidney injury molecule-1, α1-microglobuin and β2-microglobulin, were assayed at 28- and 32-wk-GA and 2-months-PP visits. Proximal tubulopathy was defined as the presence of ≥2 of the following: tubular proteinuria, euglycaemic glycosuria and increased urinary phosphate. RESULTS: A total of 291 women participated in the study. No kidney-related adverse events were severe, and none led to tenofovir disoproxil fumarate discontinuation. At 2-months-PP, 3 of the 120 (3%) evaluated women in the tenofovir disoproxil fumarate group experienced proximal tubulopathy versus 3 of 125 (2%) in the placebo group (P = 1.00). None of the six women met the criteria for proximal tubulopathy at 12-months-PP but proteinuria persisted in three of them. No growth abnormalities were found at 1 year of age in infants born to mothers with proximal tubulopathy at 2-months-PP. CONCLUSIONS: In these HBV-infected pregnant and breastfeeding women, tenofovir disoproxil fumarate administered from 28-wk-GA to 2-months-PP was not associated with a higher risk of proximal tubulopathy.
引用
- Liegeon G, Ngo-Giang-Huong N, Salvadori N, et al. Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus. J Antimicrob Chemother. 2022. PMID: 35045168. doi:10.1093/jac/dkab490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。